ECM
ARKG icon

EagleClaw Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

EagleClaw Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,250
Closed -$244K – 143
2021
Q3 		$244K Hold
3,250
– – 0.06% 121
2021
Q2 		$301K Hold
3,250
– – 0.08% 119
2021
Q1 		$289K Sell
3,250
-680
-17% -$67.5K 0.08% 114
2020
Q4 		$365K Buy
+3,930
New +$313K 0.12% 101

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

EagleClaw Capital Management's ARKG Position: Q4 2021 in Review

EagleClaw Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,250 shares — an estimated $244K sold.

EagleClaw Capital Management first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $365K in Q4 2020. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • EagleClaw Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • EagleClaw Capital Management sold 3,250 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $244K.
  • EagleClaw Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
  • EagleClaw Capital Management's ARK Genomic Revolution ETF position peaked at $365K in Q4 2020.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on EagleClaw Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.